AIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI

Dow Jones

2022-08-10

By Colin Kellaher

AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share.

The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company.

AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course.

In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing.

Write to Colin Kellaher at colin.kellaher@wsj.com

$(END)$ Dow Jones Newswires

August 10, 2022 08:48 ET (12:48 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2258216882"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2258216882\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2258216882?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-08-10 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2258216882","market":"us","top_or_hot":-1,"title":"AIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share. \n</p>\n<p>\n  The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company. \n</p>\n<p>\n  AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course. \n</p>\n<p>\n  In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 10, 2022 08:48 ET (12:48 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-08-10 20:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share. \n</p>\n<p>\n  The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company. \n</p>\n<p>\n  AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course. \n</p>\n<p>\n  In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 10, 2022 08:48 ET (12:48 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2258216882","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2258216882","pubTimestamp":1660135680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share.The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company.AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course.In a letter to AIkido","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"合气道制药从Shalom Auerbach>Aiki获得8美元/股的收购要约","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIKI":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share. \n\n\n  The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company. \n\n\n  AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course. \n\n\n  In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 10, 2022 08:48 ET (12:48 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}